Evofem Biosciences, Inc. (EVFM)
OTCMKTS · Delayed Price · Currency is USD
0.0097
-0.0002 (-2.47%)
Jul 25, 2025, 3:49 PM EDT
Evofem Biosciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | -3.1 | -8.86 | 52.98 | -76.7 | -205.19 | -142.31 | Upgrade |
Depreciation & Amortization | 0.87 | 0.65 | 0.48 | 1.02 | 1.02 | 0.3 | Upgrade |
Loss (Gain) From Sale of Assets | 0.75 | 0.73 | 2.51 | 0.93 | - | - | Upgrade |
Stock-Based Compensation | 0.68 | 0.85 | 1.19 | 3.31 | 8.9 | 12.7 | Upgrade |
Other Operating Activities | -6.1 | 1.88 | -70.85 | -4.98 | 38.03 | 39.71 | Upgrade |
Change in Accounts Receivable | 3.16 | -4.09 | -4.61 | 5.32 | -5.38 | -1.07 | Upgrade |
Change in Inventory | -1.2 | 0.06 | 2.11 | 1.57 | -0.02 | -6.01 | Upgrade |
Change in Accounts Payable | -1.96 | -0.91 | 4.09 | 4.47 | -0 | 4.13 | Upgrade |
Change in Other Net Operating Assets | 3.45 | 5.81 | 3.14 | -5.35 | 15.99 | -12.28 | Upgrade |
Operating Cash Flow | -3.45 | -3.89 | -8.97 | -70.41 | -146.67 | -104.83 | Upgrade |
Capital Expenditures | - | -0.01 | -0 | -0.34 | -2.94 | -2.25 | Upgrade |
Cash Acquisitions | -0.61 | -0.56 | - | - | - | - | Upgrade |
Divestitures | - | - | - | - | 0.25 | 0.25 | Upgrade |
Investment in Securities | - | - | - | - | - | 8.23 | Upgrade |
Investing Cash Flow | -0.61 | -0.57 | -0 | -0.34 | -2.69 | 6.23 | Upgrade |
Short-Term Debt Issued | - | 0.4 | 5.64 | - | - | 50 | Upgrade |
Long-Term Debt Issued | - | - | - | 11.5 | - | - | Upgrade |
Total Debt Issued | 0.4 | 0.4 | 5.64 | 11.5 | - | 50 | Upgrade |
Long-Term Debt Repaid | - | -0.78 | -1.15 | -5.89 | - | - | Upgrade |
Total Debt Repaid | -0.92 | -0.78 | -1.15 | -5.89 | - | - | Upgrade |
Net Debt Issued (Repaid) | -0.52 | -0.39 | 4.49 | 5.61 | - | 50 | Upgrade |
Issuance of Common Stock | 5 | 5 | 0.29 | 57.55 | 81.99 | 107.97 | Upgrade |
Repurchase of Common Stock | - | - | - | -0.02 | -0.33 | -2.87 | Upgrade |
Other Financing Activities | - | - | - | -1.2 | -0.97 | -0.87 | Upgrade |
Financing Cash Flow | 4.48 | 4.62 | 4.78 | 61.94 | 90.69 | 154.23 | Upgrade |
Net Cash Flow | 0.42 | 0.16 | -4.2 | -8.81 | -58.66 | 55.63 | Upgrade |
Free Cash Flow | -3.45 | -3.9 | -8.97 | -70.75 | -149.61 | -107.08 | Upgrade |
Free Cash Flow Margin | -20.77% | -20.14% | -49.25% | -420.21% | -1814.73% | -24009.64% | Upgrade |
Free Cash Flow Per Share | -0.04 | -0.05 | -0.01 | -151.84 | -2142.80 | -2989.73 | Upgrade |
Cash Interest Paid | 0.16 | 0.16 | 0.34 | 0.7 | 1.39 | - | Upgrade |
Cash Income Tax Paid | 0.01 | 0.01 | 0 | 0.03 | 0.01 | 0 | Upgrade |
Levered Free Cash Flow | -8.18 | -3.88 | -7.08 | -37.99 | -69.98 | -91.42 | Upgrade |
Unlevered Free Cash Flow | -6.57 | -2.27 | -5.43 | -36.68 | -67.02 | -90.12 | Upgrade |
Change in Net Working Capital | 5.3 | -1.04 | -4.06 | -11.91 | -30.25 | 36.1 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.